---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-028555"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:41:10.260125+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ChromaDex Q2 2023: Net sales $20.3M (+21%), positive Adj EBITDA, raises FY23 guidance to ≥15% growth

## Summary
- Net sales $20.3M, up 21% YoY; Tru Niagen sales $16.9M (+16%).
- Net loss narrowed to $2.2M ($0.03/sh) from $6.4M ($0.09/sh) a year ago.
- Gross margin 60.8% (+80bps); sales & marketing expense improved 1,830 bps to 29.6% of sales.
- Positive Adjusted EBITDA of $0.2M vs negative $4.7M in Q2 2022; positive operating cash flows.
- Raised FY2023 revenue outlook by 2.5% to at least 15% YoY growth.

## SEC filing metadata
- accession: 0001628280-23-028555
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828023028555/0001628280-23-028555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828023028555/cdxc-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-028555
- JSON: https://secwatch.observer/filing/0001628280-23-028555.json
- Plain text: https://secwatch.observer/filing/0001628280-23-028555.txt

## Key facts
- Earnings Releases
  Niagen Bioscience, Inc. reported the second quarter of 2023 results: revenue $20.3 million, net income $2.2 million, EPS $(0.03) per share. Guidance raised.
  - Period: the second quarter of 2023
  - Revenue: $20.3 million
  - Net income: $2.2 million
  - EPS: $(0.03) per share
  - Guidance: raised
  - Result: reported results
  source text: by specific reference in such filing. --- EX-99.1 (EX-99.1) --- ChromaDex Corporation Reports Second Quarter 2023 Financial Results Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023028555/0001628280-23-028555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.